Maccura Biotechnology Co.Ltd (SZSE: 300463)
Health Care · Life Sciences Tools & Services · CN
CN¥9.36
-3.31% today · -27.6% 1Y
Maccura Biotechnology Co.Ltd (SZSE: 300463) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $841.91M and employs 2,875 people.
Over the last twelve months the share price has lost 27.6%, trading between 7.87 and 14.20.
Tweenvest scores Maccura Biotechnology Co.Ltd across four factors: quality 67/100, value 46/100, growth 0/100. Its strongest factor is quality.
300463 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $841.91M
- Revenue (TTM)
- $313.49M
- P/E
- —
- EPS
- -0.06
- Dividend yield
- —
- Beta (5Y)
- 0.20
- 52-week high
- CN¥14.20
- 52-week low
- CN¥7.87
- Avg volume (3M)
- —
- Shares outstanding
- 604.67M
- Employees
- 2,875
- Next earnings
- —
About Maccura Biotechnology Co.Ltd
Maccura Biotechnology Co. Ltd. is an enterprise actively involved in the entire process of in vitro diagnostic (IVD) products, from their initial conceptualization and refinement (research and development) to mass production and market delivery. The company also extends related support services, catering to clientele within China and across global territories. Its diverse portfolio features immunoassay solutions, exemplified by chemiluminescence analyzers and their accompanying reagents. In the domain of clinical chemistry, Maccura furnishes reagents vital for evaluating a broad spectrum of physiological indicators, including hepatic and renal function, glucose metabolism, iron levels, specialized proteins, cardiac health, lipid profiles, and coagulation. Moreover, the firm supplies sophisticated clinical laboratory instrumentation, notably automatic hematology systems and both automated and semi-automated coagulation analyzers. The company's offerings further extend to include diagnostic tools for SARS-CoV-2 (COVID-19), such as nucleic acid detection kits and other related items. Additional products consist of glucometers, point-of-care testing (POCT) devices like fluorescence immunoassay analyzers and colloidal gold rapid test kits, molecular diagnostics (e.g., PCR kits), and a variety of pathology supplies. Maccura Biotechnology Co. Ltd. was established in 1994 and maintains its principal operations in Chengdu, China.
- ISIN
- CNE1000020H3
- Founded
- 1994
- Listed since
- May 28, 2015
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Thermo Fisher Scientific Inc.NYSE: TMO | $232.67B | $632.56 | +0.52% |
| Danaher CorporationNYSE: DHR | $153.85B | $220.60 | +0.80% |
| WuXi AppTec Co., Ltd.SHSE: 603259 | $72.12B | CN¥162.86 | -3.00% |
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $51.75B | ₩1,551,000.00 | +0.19% |
| Lonza Group AGSWX: LONN | $51.61B | CHF590.20 | -0.34% |
| Agilent Technologies, Inc.NYSE: A | $44.91B | $159.16 | +0.10% |
| IQVIA Holdings Inc.NYSE: IQV | $42.77B | $259.82 | +1.47% |
| Waters CorporationNYSE: WAT | $40.35B | $410.39 | -0.08% |
Figures last refreshed Aug 18, 2026.